These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 15877230

  • 1. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
    Digby T, Leith MK, Thliveris JA, Begleiter A.
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
    [Abstract] [Full Text] [Related]

  • 2. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
    Winski SL, Hargreaves RH, Butler J, Ross D.
    Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
    [Abstract] [Full Text] [Related]

  • 3. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
    Ward TH, Danson S, McGown AT, Ranson M, Coe NA, Jayson GC, Cummings J, Hargreaves RH, Butler J.
    Clin Cancer Res; 2005 Apr 01; 11(7):2695-701. PubMed ID: 15814651
    [Abstract] [Full Text] [Related]

  • 4. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
    Hasinoff BB, Begleiter A.
    Free Radic Res; 2006 Sep 01; 40(9):974-8. PubMed ID: 17015278
    [Abstract] [Full Text] [Related]

  • 5. Role of NADPH cytochrome P450 reductase in activation of RH1.
    Begleiter A, Leith MK, Patel D, Hasinoff BB.
    Cancer Chemother Pharmacol; 2007 Oct 01; 60(5):713-23. PubMed ID: 17256129
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
    Phillips RM, Burger AM, Loadman PM, Jarrett CM, Swaine DJ, Fiebig HH.
    Cancer Res; 2000 Nov 15; 60(22):6384-90. PubMed ID: 11103802
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
    Dehn DL, Winski SL, Ross D.
    Clin Cancer Res; 2004 May 01; 10(9):3147-55. PubMed ID: 15131056
    [Abstract] [Full Text] [Related]

  • 10. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.
    Cummings J, Ritchie A, Butler J, Ward TH, Langdon S.
    Anticancer Res; 2003 May 01; 23(5A):3979-83. PubMed ID: 14666706
    [Abstract] [Full Text] [Related]

  • 11. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
    Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D.
    Mol Pharmacol; 2008 Dec 01; 74(6):1657-65. PubMed ID: 18794327
    [Abstract] [Full Text] [Related]

  • 12. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
    Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, Ross D.
    Mol Pharmacol; 1995 Sep 01; 48(3):499-504. PubMed ID: 7565631
    [Abstract] [Full Text] [Related]

  • 13. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 01; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 14. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ.
    Nemeikaite-Ceniene A, Dringeliene A, Sarlauskas J, Cenas N.
    Acta Biochim Pol; 2005 Jun 01; 52(4):937-41. PubMed ID: 15940348
    [Abstract] [Full Text] [Related]

  • 15. RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis.
    Dehn DL, Inayat-Hussain SH, Ross D.
    J Pharmacol Exp Ther; 2005 May 01; 313(2):771-9. PubMed ID: 15665137
    [Abstract] [Full Text] [Related]

  • 16. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial.
    Danson S, Ranson M, Denneny O, Cummings J, Ward TH.
    Cancer Chemother Pharmacol; 2007 Nov 01; 60(6):851-61. PubMed ID: 17333193
    [Abstract] [Full Text] [Related]

  • 17. Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide.
    Wang X, Wang G, Dong D, Fu S, Yang B.
    Exp Toxicol Pathol; 2008 Sep 01; 60(6):481-8. PubMed ID: 18606528
    [Abstract] [Full Text] [Related]

  • 18. Cytotoxic activities of Coriolus versicolor (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis.
    Lau CB, Ho CY, Kim CF, Leung KN, Fung KP, Tse TF, Chan HH, Chow MS.
    Life Sci; 2004 Jul 02; 75(7):797-808. PubMed ID: 15183073
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR.
    Anticancer Res; 2004 Jul 02; 24(2B):907-19. PubMed ID: 15161044
    [Abstract] [Full Text] [Related]

  • 20. The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.
    Park MT, Song MJ, Oh ET, Lee H, Choi BH, Jeong SY, Choi EK, Park HJ.
    Br J Pharmacol; 2011 Jun 02; 163(3):567-85. PubMed ID: 21250978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.